ABSTRACT NUMBER: ESOC2026OT130 CONTINUOUS GLUCOSE MONITORING FOR SECONDARY STROKE PREVENTION IN PATIENTS WITH DIABETES AND PREDIABETES: A REAL-WORLD PILOT STUDY USING SIBIONICS GS1

Abstract Background and aims Patients with a history of ischemic stroke frequently present with diabetes or prediabetes, conditions associated with high glycemic variability and increased risk of recurrent cerebrovascular events. Traditional markers of glycemic control fail to capture short-term fluctuations that may contribute to vascular instability. Continuous glucose monitoring (CGM) may provide clinically relevant insights for optimizing secondary stroke prevention. Methods To evaluate glycemic profiles, variability, and time in range (TIR) using CGM in patients with prior ischemic stroke and disturbances of glucose metabolism, and to explore the feasibility of CGM-guided metabolic monitoring in secondary stroke prevention. Results This prospective observational pilot study included adult patients with a history of ischemic stroke and newly diagnosed type 2 diabetes or prediabetes. All participants underwent intermittent CGM using the Sibionics GS1 system for consecutive 14-day periods. CGM metrics included mean glucose, glycemic variability, TIR (3.9–10.0 mmol/L), time above and below range, and Glucose Management Indicator (GMI). Clinical, anthropometric, metabolic, and quality-of-life parameters were assessed at baseline and during follow-up. Conclusions Preliminary data demonstrate high TIR (86–99%), low glycemic variability (13–25%), minimal hypoglycemia, and GMI values consistent with good metabolic control. CGM revealed individual glycemic patterns not fully reflected by HbA1c or fasting glucose. The method was well tolerated and provided actionable metabolic information in this high-risk population. Conflict of interest